AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q2 FY23 results · Jul–Sep 2022
AstraZeneca Pharma India reported revenue from operations of ₹236.13 crore (up 19.4% from Q2 FY22) and net profit of ₹32.56 crore (up 172.6% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a standalone basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 236.13 | 197.71 | +19.4% | 232.33 | +1.6% |
| Other income | 6.79 | 2.84 | +139.0% | 4.11 | +65.1% |
| Total income | 242.92 | 200.55 | +21.1% | 236.45 | +2.7% |
| Profit before tax | 44.07 | 16.24 | +171.4% | 27.30 | +61.4% |
| Net profit for the period | 32.56 | 11.95 | +172.6% | 20.15 | +61.6% |
| EPS, basic (₹) | 13.03 | 4.78 | +172.6% | 8.06 | +61.6% |
| Net margin (%) | 13.8 | 6.0 | 8.7 |
Standalone
- Filed with BSE
- 12 Nov 2022, 13:32 IST
- Board meeting
- 11 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE